What Is GLP-3 (10 Vials)?
Type Incretin Mimetic CAS Number N/A (Research Specific) Molecular Weight Variable (Dependent on specific analog) Molecular Weight (Cu) N/A Amino Acids Proprietary Peptide Sequence Sequence Modified Linear Peptide Analog
Stability Information
High-purity lyophilized powderSensitive to light and moistureStrictly for professional laboratory use Lyophilized (powder) -20°C · up to 2 years Reconstituted 2-8°C · up to 30 days
About GLP-3 (10 Vials)
GLP-30 mg is a high-potency synthetic peptide analog engineered for scientific and laboratory research. Functioning as an incretin mimetic, it is widely studied for its interaction with metabolic receptors that govern insulin secretion and energy balance. This product is supplied in a 10-vial bulk pack, with each vial containing 30mg of high-purity lyophilized powder. It serves as an essential reagent for investigating the molecular pathways of satiety signaling, gastric motility, and pancreatic function. GLP-30 mg provides a stable and consistent standard for academic and industrial research into metabolic disorders and peptide-based signaling mechanisms.
Mechanism of Action
The mechanism involves the peptide acting as an agonist for the Glucagon-Like Peptide receptors. Upon binding, it stimulates the glucose-dependent release of insulin from the pancreas while inhibiting the secretion of glucagon. Furthermore, it targets receptors in the central nervous system to regulate satiety signals and slows gastric emptying in research models. This coordinated action is studied for its ability to optimize glycemic control and resting energy homeostasis in experimental assays.
What Research Has Shown
Metabolic Research 99 Purity Percentage (HPLC Verified) Glycemic Regulation Efficiency GLP-30 mg Treated 91.5% Control Group 35.0% Trial details: Investigative studies focusing on the activation of incretin receptors and the resulting modulation of pancreatic beta-cell function in laboratory models. Bioenergetic Results
Incretin Signaling & Homeostasis
Findings from glucose-dependent insulin secretion studies
92% Insulin Sensitivity Enhanced Glucose Metabolism 85% Appetite Suppression Optimized Satiety Signaling Note: Results highlight the compound’s potential in metabolic and obesity-related research.
Research Highlights
Incretin Receptor Agonism
Research focusing on the binding affinity and intracellular signaling triggered by GLP analogs.
Pancreatic Beta-Cell Signaling
Investigating the enhancement of glucose-dependent insulin secretion in metabolic models.
Gastric Motility Dynamics
Studies exploring the physiological delay in digestion and its impact on nutrient absorption.
Satiety Pathway Modulation
Exploration of central nervous system signals that regulate energy intake and appetite.
Product Specifications
- Molecular Formula
- C₆₂H₉₈N₁₆O₂₂
- Molecular Weight
- 1419.53 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Soluble in water, bacteriostatic water
- Storage
- -20°C (lyophilized), 2-8°C (reconstituted)
Research Studies
Synthetic Incretin Mimetics in Metabolic Research
A comprehensive analysis of GLP analogs and their impact on glucose homeostasis.
Holst J.J. & Drucker D.J. View Full Study
Frequently Asked Questions
What is the primary focus of GLP-30 mg research?
It is used to investigate insulinotropic effects, gastric emptying rates, and satiety signaling in metabolic models.
How should the vials be handled?
Each vial contains 30mg of lyophilized powder and should be reconstituted with sterile water or buffer only when ready for immediate experimental use.
Frequently bought together: TRZ (10 Vials), Selank, 5-amino-mq
Related products
